Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)
Research type
Research Study
Full title
MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia
IRAS ID
282552
Contact name
Nichola Cooper
Contact email
Sponsor organisation
Joint Research Compliance Office
Eudract number
2020-001750-22
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 7 months, 1 days
Research summary
COVID-19 is caused by a type of coronavirus not previously identified in humans. It emerged in China in November 2019 and has now spread across the world. The World Health Organisation declared a pandemic on 11 March 2020.
To date, there is no vaccine or specific antiviral medicine shown to be effective in preventing or treating COVID-19. Patients with mild disease recover with symptomatic treatment and supportive care. Patients with severe illness require hospitalisation and may develop COVID-19 pneumonia. Much of the destructive part of the disease appears to be caused by tissue damage in the lung and a resultant inflammatory response. The acute inflammatory response is responsible for acute respiratory deterioration requiring ventilation and with a high morbidity and mortality.
Therapeutic interventions targeting inflammatory signalling have been used to ameliorate the inflammatory response. Further understanding of this pathways, and re-purposing of immunomodulatory treatments might reduce the severity of the inflammatory response phase, resulting in amelioration of the lung damage, thereby averting respiratory failure and the need for mechanical ventilation.
This study aims to evaluate the safety and efficacy of two inhibitors (ruxolitinib and fostamatinib) of key inflammatory signalling pathways compared with standard of care in hospitalised patients with COVID-19 pneumonia.
This study will be funded by NIHR Imperial Biomedical Research Centre and research will take place across ICHT.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
20/HRA/2618
Date of REC Opinion
26 May 2020
REC opinion
Favourable Opinion